Clinical Trial Update: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of dasatinib, paclitaxel, and carboplatin in patients with Stage III-IV or recurrent endometrial cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Clear Cell Adenocarcinoma
• Endometrial Mucinous Adenocarcinoma
• Endometrial Serous Adenocarcinoma
• Endometrial Squamous Cell Carcinoma
• Endometrial Transitional Cell Carcinoma
• Endometrial Undifferentiated Carcinoma
• Endometrioid Adenocarcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DASATINIB (Dasatinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Status: COMPLETED